Related Experiment Video

Updated: May 27, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M

Jixia Li1, Feng Zhu, Ronald A Lubet

  • 1The Hormel Institute, University of Minnesota, Austin, Minnesota 55912, USA.

Molecular Carcinogenesis
|November 17, 2011
PubMed

Insights

Quercetin-3-methyl ether effectively inhibits growth in lapatinib-sensitive and -resistant breast cancer cells by inducing cell cycle arrest and apoptosis. This natural compound shows promise as a therapeutic agent for breast cancer patients resistant to lapatinib.

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Lapatinib is a targeted therapy for HER2-positive breast cancer, but resistance limits its efficacy.
  • Natural compounds are being explored for cancer treatment due to their potential low toxicity.
  • Quercetin-3-methyl ether, a plant-derived compound, exhibits anticancer properties.

Purpose of the Study:

  • To investigate the efficacy of quercetin-3-methyl ether against lapatinib-sensitive and -resistant breast cancer cells.
  • To elucidate the mechanisms of action of quercetin-3-methyl ether in breast cancer cells.
  • To evaluate quercetin-3-methyl ether as a potential therapeutic agent for lapatinib-resistant breast cancer.

Main Methods:

  • Cell viability assays were performed on lapatinib-sensitive and -resistant breast cancer cell lines.
  • Western blot analysis was used to assess signaling pathways (Akt, ERKs) and cell cycle regulators (Chk1, Cdc25c, cyclin B1, Cdk1, cyclin D1).
  • Apoptosis was evaluated by measuring cleaved caspase 3, caspase 7, and PARP levels.

Main Results:

  • Quercetin-3-methyl ether significantly inhibited the growth of both lapatinib-sensitive and -resistant breast cancer cells.
  • Quercetin-3-methyl ether induced a G(2)/M cell cycle arrest via the Chk1-Cdc25c-cyclin B1/Cdk1 pathway in both cell types.
  • Lapatinib induced G(1) arrest only in sensitive cells via cyclin D1; quercetin-3-methyl ether induced apoptosis in both cell lines.

Conclusions:

  • Quercetin-3-methyl ether demonstrates potent anticancer activity against lapatinib-sensitive and -resistant breast cancer cells.
  • The compound acts through distinct mechanisms, including G(2)/M cell cycle arrest and apoptosis induction.
  • Quercetin-3-methyl ether represents a promising therapeutic candidate for overcoming lapatinib resistance in breast cancer.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...